Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ariad Pharmaceuticals, an oncology company, has appointed Massimo Radaelli and Wayne Wilson to its board of directors.
Subscribe to our email newsletter
Dr Radaelli is the president and CEO of Dompe International. He currently serves on the board of directors of Dompe Farmaceutici SpA, Dompe SpA, and Philogen SpA, a privately held Italian biopharmaceutical company.
Dr Radaelli has received a University degree in pharmaceutical sciences and a PhD in clinical pharmacology from the University of Milan and an executive master of business from Bocconi University of Milan.
Mr Wilson currently serves on the board of directors of Hologic. Mr Wilson has received an AB degree in political science from Duke University and an MBA with concentration in accounting and finance from the University of North Carolina at Chapel Hill. Mr Wilson will chair the board’s audit committee.
Harvey Berger, chairman and CEO of Ariad, said: “Massimo is a pharmaceutical executive with an in-depth understanding of global product strategy, drug commercialization and corporate development. Wayne brings extensive experience as a corporate director and executive of public companies and as an audit committee financial expert to our board. I look forward to working closely with both of them as we transform Ariad to a fully integrated oncology company with marketed products and a strong, promising pipeline.”